Lilly Reports Favorable Cyramza Results in Phase 3 Liver Cancer Trial
January 18 2019 - 8:23PM
Dow Jones News
By Josh Beckerman
Eli Lilly & Co. (LLY) reported favorable results for its
Cyramza cancer drug in the Phase 3 Reach-2 trial with liver cancer
patients.
The company said Reach-2 showed a statistically significant
improvement in the primary endpoint of overall survival and in the
secondary endpoint of progression-free survival.
The trial evaluated the drug with a biomarker-selected patient
population.
Cyramza, currently approved for some patients with conditions
including gastric cancer, is being investigated in a development
program that has enrolled more than 14,000 patients in over 100
trials.
Write to Josh Beckerman at josh.beckerman@wsj.com
(END) Dow Jones Newswires
January 18, 2019 20:08 ET (01:08 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Eli Lilly (NYSE:LLY)
Historical Stock Chart
From Aug 2024 to Sep 2024
Eli Lilly (NYSE:LLY)
Historical Stock Chart
From Sep 2023 to Sep 2024